| Property | Value |
|---|
|
?:abstract
|
-
Using convalescent plasma as immunotherapy is an old method for treatment of infectious diseases Several countries have recently allowed the use of such therapy for the treatment of COVID-19 patients especially those who are critically ill A similar program is currently being tested in Egypt Here, we tested 227 plasma samples from convalescent donors in Egypt for neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using a microneutralization (MN) assay A third of the tested samples did not have antibody titers and 58% had titers between 1:10 and 1:80 Only 12% had titers >1:160 We also compared MN assays using different virus concentrations, plaque reduction neutralization (PRNT) assays, and a chemiluminescence assay that measures immunoglobulin G (IgG) binding to N and S proteins of SARS-CoV-2 Our results indicated that a MN assay using 100 TCID50/ml provides comparable results to PRNT and allows for high throughput testing
|
|
is
?:annotates
of
|
|
|
?:creator
|
|
|
?:journal
|
|
|
?:license
|
|
|
?:publication_isRelatedTo_Disease
|
|
|
is
?:relation_isRelatedTo_publication
of
|
|
|
?:source
|
|
|
?:title
|
-
Prevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibodies in Egyptian Convalescent Plasma Donors
|
|
?:type
|
|
|
?:who_covidence_id
|
|
|
?:year
|
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}